| scholarly article | Q13442814 |
| P356 | DOI | 10.1586/ECP.12.19 |
| P698 | PubMed publication ID | 22697594 |
| P2093 | author name string | Alexandros D Tselepis | |
| Kallirroi I Kalantzi | |||
| Ioannis A Goudevenos | |||
| Maria E Tsoumani | |||
| P2860 | cites work | Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients | Q24555072 |
| Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis | Q24645413 | ||
| Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke | Q24646522 | ||
| Anti-glycoprotein VI treatment severely compromises hemostasis in mice with reduced alpha2beta1 levels or concomitant aspirin therapy | Q28171295 | ||
| Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting | Q28191931 | ||
| Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation | Q28192958 | ||
| Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial | Q28194232 | ||
| Antiplatelet drugs | Q28194430 | ||
| Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study: a randomized, double-blind, multicenter trial | Q28195452 | ||
| Dipyridamole selectively inhibits inflammatory gene expression in platelet-monocyte aggregates | Q28213662 | ||
| Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial | Q28218263 | ||
| Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation | Q28218789 | ||
| Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial | Q28218952 | ||
| Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis | Q28219463 | ||
| Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use | Q28263273 | ||
| Epitope mapping of inhibitory antibodies against platelet glycoprotein Ibalpha reveals interaction between the leucine-rich repeat N-terminal and C-terminal flanking domains of glycoprotein Ibalpha. | Q30691871 | ||
| A consensus tetrapeptide selected by phage display adopts the conformation of a dominant discontinuous epitope of a monoclonal anti-VWF antibody that inhibits the von Willebrand factor-collagen interaction | Q30961540 | ||
| The Fab fragment of a novel anti-GPVI monoclonal antibody, OM4, reduces in vivo thrombosis without bleeding risk in rats | Q33374356 | ||
| Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects | Q33384521 | ||
| Discovery and development of therapeutic aptamers. | Q33522441 | ||
| Thromboxane and the thromboxane receptor in cardiovascular disease | Q33899567 | ||
| Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. | Q34020220 | ||
| Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction | Q34168972 | ||
| Thrombin-receptor antagonist vorapaxar in acute coronary syndromes | Q34231934 | ||
| Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease | Q34255442 | ||
| Vorapaxar in the secondary prevention of atherothrombotic events | Q34263311 | ||
| Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis | Q34564576 | ||
| Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis | Q34624862 | ||
| Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease | Q34633709 | ||
| Clopidogrel with or without omeprazole in coronary artery disease | Q34660303 | ||
| The pharmacology of cilostazol | Q34785781 | ||
| Cytochrome p-450 polymorphisms and response to clopidogrel | Q34910228 | ||
| Novel agents for anti-platelet therapy | Q35574825 | ||
| Protease-activated receptors: contribution to physiology and disease | Q35715253 | ||
| Protease-activated receptors in hemostasis, thrombosis and vascular biology | Q36230881 | ||
| Access of HTB, main metabolite of triflusal, to cerebrospinal fluid in healthy volunteers. | Q45265599 | ||
| A randomised study comparing the antiplatelet and antiinflammatory effect of clopidogrel 150 mg/day versus 75 mg/day in patients with ST-segment elevation acute myocardial infarction and poor responsiveness to clopidogrel: results from the DOUBLE st | Q45928517 | ||
| Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: a meta-analysis. | Q45969556 | ||
| Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study. | Q46000156 | ||
| Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy | Q46046935 | ||
| Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients | Q46047927 | ||
| Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Pati | Q46073177 | ||
| Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study | Q46088369 | ||
| Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis | Q46187200 | ||
| Basic and translational research on proteinase-activated receptors: antagonism of the proteinase-activated receptor 1 for thrombin, a novel approach to antiplatelet therapy for atherothrombotic disease | Q46189242 | ||
| Multiple antiplatelet effects of clopidogrel are not modulated by statin type in patients undergoing percutaneous coronary intervention | Q46374395 | ||
| The specific thromboxane receptor antagonist S18886: pharmacokinetic and pharmacodynamic studies. | Q46566202 | ||
| Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study | Q46665436 | ||
| Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myoc | Q46868498 | ||
| Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions. | Q50525288 | ||
| Gastrointestinal safety of triflusal solution in healthy volunteers: a proof of concept endoscopic study. | Q51602399 | ||
| The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale. | Q53499051 | ||
| Pharmacology and clinical trials of reversibly-binding P2Y12 inhibitors. | Q55054169 | ||
| Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: Design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)- | Q57313076 | ||
| Platelet activation and atherothrombosis | Q37031278 | ||
| Cell adhesion mechanisms in platelets | Q37049884 | ||
| von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes. | Q37112364 | ||
| The genetics of antiplatelet drug resistance | Q37344920 | ||
| Advances in antiplatelet therapy: agents in clinical development | Q37376472 | ||
| TP receptor antagonism: a new concept in atherothrombosis and stroke prevention | Q37480448 | ||
| P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. | Q37562606 | ||
| Stroke prevention by cilostazol in patients with atherothrombosis: meta-analysis of placebo-controlled randomized trials | Q37629990 | ||
| Antiplatelet therapies for the treatment of cardiovascular disease | Q37684794 | ||
| Mechanism of action and clinical development of platelet thrombin receptor antagonists. | Q37776518 | ||
| Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. | Q37786695 | ||
| Glycoprotein IIb/IIIa inhibitors: an update on the mechanism of action and use of functional testing methods to assess antiplatelet efficacy | Q37841572 | ||
| Clopidogrel-drug interactions | Q37851658 | ||
| Antiplatelet therapy: thrombin receptor antagonists | Q37929838 | ||
| Antiplatelet agents for the treatment and prevention of atherothrombosis | Q37948506 | ||
| First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers | Q38296268 | ||
| Inhibition of von Willebrand factor-mediated platelet activation and thrombosis by the anti-von Willebrand factor A1-domain aptamer ARC1779. | Q38354361 | ||
| Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin–Acute Coronary Syndromes Trial | Q38492131 | ||
| Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin–Coronary Artery Disease Trial | Q38492142 | ||
| Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial | Q38493350 | ||
| Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial | Q38500562 | ||
| GPVI and alpha2beta1 play independent critical roles during platelet adhesion and aggregate formation to collagen under flow | Q42194347 | ||
| European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke | Q42551725 | ||
| Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Ear | Q42641710 | ||
| Secondary prevention of stroke: can we do better than aspirin? | Q42910107 | ||
| Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percuta | Q42990922 | ||
| Engineering and characterization of a chimeric anti-platelet glycoprotein Ibalpha monoclonal antibody and preparation of its Fab fragment | Q43073628 | ||
| Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome | Q43177299 | ||
| Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in | Q43179454 | ||
| Association of platelet responsiveness with clopidogrel metabolism: role of compliance in the assessment of "resistance". | Q43230594 | ||
| Intravenous platelet blockade with cangrelor during PCI. | Q43241907 | ||
| Platelet inhibition with cangrelor in patients undergoing PCI. | Q43241909 | ||
| The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients | Q43264421 | ||
| Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes | Q43445863 | ||
| Pharmacokinetics and pharmacodynamics of AJW200, a humanized monoclonal antibody to von Willebrand factor, in monkeys | Q43852844 | ||
| Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patien | Q44475877 | ||
| GPVI levels in platelets: relationship to platelet function at high shear | Q44493355 | ||
| Identification of the primary collagen-binding surface on human glycoprotein VI by site-directed mutagenesis and by a blocking phage antibody | Q44592655 | ||
| Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function — a flow cytometry study | Q44604925 | ||
| Effect of synthetic peptides corresponding to residues 313-332 of the alphaIIb subunit on platelet activation and fibrinogen binding to alphaIIbbeta3. | Q44756625 | ||
| Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. | Q44801358 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacodynamics | Q725307 |
| P304 | page(s) | 319-336 | |
| P577 | publication date | 2012-05-01 | |
| P1433 | published in | Expert Review of Clinical Pharmacology | Q15793519 |
| P1476 | title | Pharmacodynamic properties of antiplatelet agents: current knowledge and future perspectives | |
| P478 | volume | 5 |
| Q90672492 | Antithrombotic Agents and Cancer |
| Q39089774 | Curbing tumorigenesis and malignant progression through the pharmacological control of the wound healing process |
| Q39660267 | Dynamic platelet adhesion in patients with an acute coronary syndrome: The effect of antiplatelet therapy |
| Q36094523 | Increased Benefit With Vorapaxar Use in Patients With a History of Myocardial Infarction and Diabetes Mellitus: What the Data Show Us. |
| Q37139179 | Influence of genetic variations on levels of inflammatory markers of healthy subjects at baseline and one week after clopidogrel therapy; results of a preliminary study |
| Q47256757 | Microfludic platforms for the evaluation of anti-platelet agent efficacy under hyper-shear conditions associated with ventricular assist devices. |
| Q92068084 | Molecular Requirements for the Expression of Antiplatelet Effects by Synthetic Structural Optimized Analogues of the Anticancer Drugs Imatinib and Nilotinib |
| Q36314883 | P2Y12 Receptor Localizes in the Renal Collecting Duct and Its Blockade Augments Arginine Vasopressin Action and Alleviates Nephrogenic Diabetes Insipidus. |
| Q35602671 | Targeting renal purinergic signalling for the treatment of lithium-induced nephrogenic diabetes insipidus. |
| Q92013764 | The Effect of Mushroom Extracts on Human Platelet and Blood Coagulation: In vitro Screening of Eight Edible Species |
| Q92025973 | The Role of Eicosanoids in Alzheimer's Disease |
Search more.